Study: Femara reduces risk of breast cancer recurrence

03/10/2008 | MSNBC

Researchers found that taking Femara, Novartis AG's breast cancer pill, up to seven years after finishing tamoxifen therapy lowered the risk of breast cancer recurrence in post-menopausal patients by 63%. The drug, an aromatase inhibitor, slashed metastasis risk by 61% and lowered the risk of tumor growth in the unaffected breast by more than 80% percent, according to the study.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN